Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Results of the First Italian External Quality Assurance Scheme for somatic EGFR mutation testing in non-small-cell lung cancer.

Normanno N, Pinto C, Taddei G, Gambacorta M, Castiglione F, Barberis M, Clemente C, Marchetti A.

J Thorac Oncol. 2013 Jun;8(6):773-8. doi: 10.1097/JTO.0b013e31828c2b08.

2.

ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: results of the first italian external quality assurance scheme.

Marchetti A, Barberis M, Papotti M, Rossi G, Franco R, Malatesta S, Buttitta F, Ardizzoni A, Crinò L, Gridelli C, Taddei GL, Clemente C, Scagliotti G, Normanno N, Pinto C.

J Thorac Oncol. 2014 Oct;9(10):1470-6. doi: 10.1097/JTO.0000000000000280.

3.

Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing.

Patton S, Normanno N, Blackhall F, Murray S, Kerr KM, Dietel M, Filipits M, Benlloch S, Popat S, Stahel R, Thunnissen E.

Br J Cancer. 2014 Jul 15;111(2):413-20. doi: 10.1038/bjc.2014.353. Epub 2014 Jul 1.

4.

The Italian external quality assessment for RAS testing in colorectal carcinoma identifies methods-related inter-laboratory differences.

Normanno N, Pinto C, Castiglione F, Fenizia F, Barberis M, Marchetti A, Fontanini G, De Rosa G, Taddei GL.

J Transl Med. 2015 Sep 3;13:287. doi: 10.1186/s12967-015-0655-1.

5.

Improvement in the quality of molecular analysis of EGFR in non-small-cell lung cancer detected by three rounds of external quality assessment.

Deans ZC, Bilbe N, O'Sullivan B, Lazarou LP, de Castro DG, Parry S, Dodson A, Taniere P, Clark C, Butler R.

J Clin Pathol. 2013 Apr;66(4):319-25. doi: 10.1136/jclinpath-2012-201227. Epub 2013 Feb 1.

PMID:
23378269
6.

KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment.

Normanno N, Pinto C, Castiglione F, Bardelli A, Gambacorta M, Botti G, Nappi O, Siena S, Ciardiello F, Taddei G, Marchetti A.

PLoS One. 2011;6(12):e29146. doi: 10.1371/journal.pone.0029146. Epub 2011 Dec 21.

7.

Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis.

Westwood M, Joore M, Whiting P, van Asselt T, Ramaekers B, Armstrong N, Misso K, Severens J, Kleijnen J.

Health Technol Assess. 2014 May;18(32):1-166. doi: 10.3310/hta18320. Review.

8.

The relevance of external quality assessment for molecular testing for ALK positive non-small cell lung cancer: results from two pilot rounds show room for optimization.

Tembuyser L, Tack V, Zwaenepoel K, Pauwels P, Miller K, Bubendorf L, Kerr K, Schuuring E, Thunnissen E, Dequeker EM.

PLoS One. 2014 Nov 11;9(11):e112159. doi: 10.1371/journal.pone.0112159. eCollection 2014.

9.

EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey.

Yatabe Y, Kerr KM, Utomo A, Rajadurai P, Tran VK, Du X, Chou TY, Enriquez ML, Lee GK, Iqbal J, Shuangshoti S, Chung JH, Hagiwara K, Liang Z, Normanno N, Park K, Toyooka S, Tsai CM, Waring P, Zhang L, McCormack R, Ratcliffe M, Itoh Y, Sugeno M, Mok T.

J Thorac Oncol. 2015 Mar;10(3):438-45. doi: 10.1097/JTO.0000000000000422.

10.

Challenges to implementation of an epidermal growth factor receptor testing strategy for non-small-cell lung cancer in a publicly funded health care system.

Ellis PM, Verma S, Sehdev S, Younus J, Leighl NB.

J Thorac Oncol. 2013 Sep;8(9):1136-41. doi: 10.1097/JTO.0b013e31829f6a43.

11.

EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients.

Malapelle U, Bellevicine C, De Luca C, Salatiello M, De Stefano A, Rocco D, de Rosa N, Vitiello F, Russo S, Pepe F, Iaccarino A, Micheli P, Illiano A, Carlomagno C, Piantedosi FV, Troncone G.

Cancer Cytopathol. 2013 Oct;121(10):552-60. doi: 10.1002/cncy.21322. Epub 2013 Jun 18.

12.

[Detection of epidermal growth factor receptor mutations in non-small cell lung cancer by real-time PCR using TaqMan-MGB probes].

Zhou CC, Zhou SW, Pan H, Su B, Gao ZQ.

Zhonghua Zhong Liu Za Zhi. 2007 Feb;29(2):119-23. Chinese.

PMID:
17645848
13.

A novel point-of-care system for high-speed real-time polymerase chain reaction testing for epidermal growth factor receptor mutations in bronchial lavage fluids after transbronchial biopsy in patients with non-small cell lung cancer.

Sakamoto T, Kodani M, Takata M, Chikumi H, Nakamoto M, Nishii-Ito S, Ueda Y, Izumi H, Makino H, Touge H, Takeda K, Yamasaki A, Yanai M, Tanaka N, Igishi T, Shimizu E.

Int J Oncol. 2015 Apr;46(4):1473-80. doi: 10.3892/ijo.2015.2875. Epub 2015 Feb 4.

14.

Detection of epidermal growth factor receptor mutations in a few cancer cells from transbronchial cytologic specimens by reverse transcriptase-polymerase chain reaction.

Kanaji N, Bandoh S, Ishii T, Kushida Y, Haba R, Kohno K, Dobashi H, Ohnishi H, Matsunaga T.

Mol Diagn Ther. 2011 Dec 1;15(6):353-9. doi: 10.2165/11595700-000000000-00000.

PMID:
22117119
15.

Highly sensitive detection of EGFR T790M mutation using colony hybridization predicts favorable prognosis of patients with lung cancer harboring activating EGFR mutation.

Fujita Y, Suda K, Kimura H, Matsumoto K, Arao T, Nagai T, Saijo N, Yatabe Y, Mitsudomi T, Nishio K.

J Thorac Oncol. 2012 Nov;7(11):1640-4. doi: 10.1097/JTO.0b013e3182653d7f.

16.

A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells.

Molina-Vila MA, Bertran-Alamillo J, Reguart N, Taron M, Castellà E, Llatjós M, Costa C, Mayo C, Pradas A, Queralt C, Botia M, Pérez-Cano M, Carrasco E, Tomàs M, Mate JL, Moran T, Rosell R.

J Thorac Oncol. 2008 Nov;3(11):1224-35. doi: 10.1097/JTO.0b013e318189f579.

17.

Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach.

Salto-Tellez M, Tsao MS, Shih JY, Thongprasert S, Lu S, Chang GC, Au JS, Chou TY, Lee JS, Shi YK, Radzi A, Kang JH, Kim SW, Tan SY, Yang JC.

J Thorac Oncol. 2011 Oct;6(10):1663-9. doi: 10.1097/JTO.0b013e318227816a.

18.

High expression of dihydropyrimidine dehydrogenase in lung adenocarcinoma is associated with mutations in epidermal growth factor receptor: implications for the treatment of non--small-cell lung cancer using 5-fluorouracil.

Mochinaga K, Tsuchiya T, Nagasaki T, Arai J, Tominaga T, Yamasaki N, Matsumoto K, Miyazaki T, Nanashima A, Hayashi T, Tsukamoto K, Nagayasu T.

Clin Lung Cancer. 2014 Mar;15(2):136-144.e4. doi: 10.1016/j.cllc.2013.09.002. Epub 2013 Nov 14.

PMID:
24405586
19.

Outcomes of an Australian testing programme for epidermal growth factor receptor mutations in non-small cell lung cancer.

Peters MJ, Bowden JJ, Carpenter P, Lewis J, Solomon B.

Intern Med J. 2014 Jun;44(6):575-80. doi: 10.1111/imj.12449.

PMID:
24720523
20.

High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features.

Sun PL, Seol H, Lee HJ, Yoo SB, Kim H, Xu X, Jheon S, Lee CT, Lee JS, Chung JH.

J Thorac Oncol. 2012 Feb;7(2):323-30. doi: 10.1097/JTO.0b013e3182381515.

Supplemental Content

Support Center